CareMetx

Among a variety of Hub vendors, what specific qualities distinguish differentiated support for drug manufacturers? To help answer this question, CareMetx conducted in-depth interviews and surveys with senior leadership at top manufacturers.

In a recent study, CareMetx engaged with senior leadership at leading biopharmaceutical manufacturers, aiming to evaluate the optimal ways in which Hub data can enhance manufacturer support. These findings can serve as a valuable guide for manufacturers seeking insights on optimizing their utilization of Hub data.

CareMetx, a Hub services company that provides high-touch support to drive therapy initiation and adherence, conducted research involving over 100 participants, using both qualitative and quantitative methods. The primary aim was to understand how therapy manufacturers envision the future of Hubs.

Throughout the specialty pharmacy industry, leaders are beginning to spend more time thinking about the overall patient experience, and how patients benefit from having quicker access to therapy. In this conversation, CareMetx Chief Patient Experience Officer Jessica Lens dives deeper into the patient experience- particularly in the early treatment phases, helping us understand patient behavior around initiating and taking medication, and how to impact that behavior. In short- we discuss a need to broaden the scope of what we currently call “adherence” to consider the reality that patient medication taking attitudes, beliefs, mindset, and behavior - starts long before the first dose.

Throughout the specialty pharmacy industry, leaders are beginning to spend more time thinking about the overall patient experience, and how patients benefit from having quicker access to therapy. In this conversation, CareMetx Chief Patient Experience Officer Jessica Lens dives deeper into the patient experience- particularly in the early treatment phases, helping us understand patient behavior around initiating and taking medication, and how to impact that behavior. In short- we discuss a need to broaden the scope of what we currently call “adherence” to consider the reality that patient medication taking attitudes, beliefs, mindset, and behavior - starts long before the first dose.